Sandoz launches oncology generic gefitinib in 13 EU countries

Sandoz launches oncology generic gefitinib in 13 EU countries

Source: 
Pharmaceutical Business Review
snippet: 


Sandoz has announced the launch of the generic oncology medicine gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK, which is recommended by ESMO as first-line treatment.